Visceral leishmaniasis during pegylated interferon therapy for chronic hepatitis C: first report.
Cascio
Antonio
A
Antinori
Spinello
S
Ricciardi
Filippo
F
Costantino
Giuseppo
G
Iaria
Chiara
C
D000328:Adult; D000666:Amphotericin B / Q000627:therapeutic use; D000981:Antiprotozoal Agents / Q000627:therapeutic use; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use; D007898:Leishmaniasis, Visceral / Q000139:chemically induced* / Q000188:drug therapy; D008297:Male; D011092:Polyethylene Glycols / Q000009:adverse effects* / Q000627:therapeutic use; D011994:Recombinant Proteins
D000981:Antiprotozoal Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D000666:Amphotericin B; C100416:peginterferon alfa-2a